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Abstract 
Human alpha1-acid glycoprotein (AGP) is an acute phase glycoprotein that 
has a heterogeneous glycosylation pattern. This pattern can change in certain 
diseases, which has resulted in interest in using AGP glycoforms as potential 
biomarkers for these diseases. This report describes a method that uses cap-
illary electrophoresis to characterize and analyze AGP glycoforms both in pu-
rified samples of AGP and in human serum. This method uses static and dy-
namic coatings of poly (ethylene oxide) that are applied to a silica capillary 
for separation of AGP glycoforms in the reversed-polarity mode of CE and in 
the presence of negligible electroosmotic flow. Electrophoretic injection is 
performed onto such capillaries by using a stationary stacking interface be-
tween the sample and running buffer. In addition, acidic precipitation and de-
salting are used to allow for the isolation and the analysis of AGP from only 
65 μL of serum. Up to eleven AGP glycoform bands can be reproducibly sep-
arated by this method, with the difference in migration time between neigh-
boring bands being 12- to almost 60-fold larger than the standard deviation 
for the migration time of any given band. A limit of detection down to about 
2 nM per glycoform band can be obtained by this method for AGP in serum 
based on absorbance detection and without the need for further sample mod-
ification or labeling. 
Key words: Alpha1-acid glycoprotein, Capillary electrophoresis, Capillary 
modification, Electrophoretic injection, Glycoforms, Sample stacking, Serum 
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1 Introduction 
Human alpha1-acid glycoprotein (AGP) is an acute phase glyco-
protein that has a single chain of 183 amino acids and two disul-
fide bonds [1–3]. AGP is a heavily glycosylated protein. The molecular 
weight of AGP is between 41 and 43 kDa, with about 45% of this mass 
being due to glycan moieties [1]. As shown in Fig. 1, there are five N-
linked glycosylation sites on AGP, which occur at Asn15, Asn38, Asn54, 
Asn75, and Asn85. A heterogeneous mixture of bi-, tri-, or tetra-an-
tennary glycans can be attached to these sites [1]. AGP has a low iso-
electric point (2.8 to 3.8) due to the presence of multiple sialic acids 
in these glycan chains [1, 2]. 
Both the concentration and composition of AGP can change with 
various diseases and clinical conditions [2, 4–7]. For instance, the nor-
mal concentration of AGP in serum ranges from 0.5 to 1.0 mg/mL, or 
12 to 24 μM; however, this concentration can increase by up to ten-
fold in some clinical situations [2]. In addition, alterations in the gly-
cosylation of AGP have been observed. For instance, a decrease in the 
degree of glycan branching has been reported in patients with infec-
tion and systemic lupus erythematosus (SLE) [4]. An increase in α1–3 
fucosylation has been noted in pancreatic cancer [5], and an increase 
in levels of AGP sialylation has been seen in ovarian cancer and lym-
phoma [6, 7]. These changes have made AGP glycoforms and their 
related glycosylation patterns of interest as potential biomarkers for 
these and other disease states [4–7]. 
Fig. 1 Examples of complex N-linked glycans that can occur on AGP and the loca-
tions of the glycosylation sites on AGP. Abbreviations: GlcNAc N-acetylglucosamine, 
Man mannose, Gal galactose, Fuc fucose, NeuAc neuraminic acid (or sialic acid). 
The nomenclature used here for the representation of glycans is based on Ref. [24]. 
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Capillary electrophoresis (CE) is one approach that can be used to 
separate and examine the glycoforms of AGP [6, 8–11]. During the 
development of these CE methods, various approaches have been 
proposed to reduce adsorption of AGP onto the capillary wall and to 
modify electroomostic flow for improved precision and better reso-
lution of the glycoform bands. These approaches have included the 
use of buffer additives such as putrescine and urea or the use of cap-
illaries that contained a cross-linked coating of dimethylpolysiloxane 
[6, 8–10]. In this report, an alternative method was employed in which 
static and dynamic coatings of poly (ethylene oxide) (PEO) were ap-
plied to a silica capillary. This coating method was used because it has 
been shown to allow highly reproducible separations of AGP glyco-
forms and to provide differences in migration times between neigh-
boring glycoform bands that are 12- to almost 60-fold larger than the 
standard deviations of the migration times for these bands [11]. In this 
report, these coated capillaries were combined with electrophoretic 
injection and UV absorbance detection to examine the major glyco-
form bands of human AGP. 
The use of absorbance detection alone for AGP tends to provide 
only modest detection limits in CE due to the short path length of 
light in the capillary and the capillary’s small loading capacity [12]. For 
instance, a limit of detection of 0.09–0.38 μM is obtained for the gly-
coform bands of AGP when absorbance detection is employed with 
standard hydrodynamic injection [11]. Mass spectrometry is an alter-
native detection method that has been used with CE, in combination 
with immunoaffinity extraction, to examine AGP glycoforms in serum; 
however, the cost of the instrumentation and level of training needed 
for CE-mass spectrometry has tended to limit its use in routine clini-
cal testing [13–15]. CE with laser-induced fluorescence detection and 
fluorescent-labeled AGP can also be used to detect AGP glycoforms 
[16], but this approach adds extra steps and time for sample treat-
ment and modifies the structure of AGP. Electrophoretic injection is a 
type of electrokinetic injection that can be performed with AGP when 
there is a negligible amount of electroosmotic flow present in this sys-
tem [17]. This situation creates an essentially stationary stacking in-
terface between the sample and running buffer during injection. This 
technique can allow for the sensitive detection of AGP (i.e., down to 
0.05–0.2 nM) without the need for AGP derivatization and by using 
absorbance detection [17]. 
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Sample pretreatment was further needed to use CE with absor-
bance detection and electrophoretic injection for the analysis of AGP 
in serum (see overall scheme provided in Fig. 2). Multiple chromato-
graphic steps, such as ion-exchange and dye-ligand chromatography, 
have been used to isolate AGP from serum or plasma; unfortunately, 
this approach generally requires a relatively large sample volume [18, 
19]. Immunoaffinity extraction with anti- AGP immobilized support 
has been used as well but needs multiple steps for sample loading, 
elution, and column regeneration [20]. Acidic precipitation has been 
employed for the pretreatment of AGP from plasma but tends to give 
a low purity for AGP when compared with immunoaffinity extraction 
[20, 21]. The method that is described in this current report combined 
acidic precipitation, desalting, and electrokinetic injection for the se-
lective enrichment of AGP from serum using sample volumes of as 
little as 65 μL [17]. 
Fig. 2 General scheme for the sample preparation and CE analysis of glycoform 
bands for AGP that has been isolated from serum.  
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2 Materials 
The water used in the following procedures was prepared with a 
Milli-Q water purification system (EMD Millipore Corporation); how-
ever, other types of water purification systems can also be used. 
2.1 Samples 
1. Commercial samples of normal human AGP (≥99% purity, from 
pooled human plasma) were obtained from Sigma- Aldrich. 
2. Commercial samples of human serum were also obtained from 
Sigma-Aldrich, as were made from pooled human male AB plasma 
of U.S. origin (sterile-filtered). Each donor that was used to prepare 
this commercial sample had been tested by ELISA and found to be 
nonreactive for hepatitis B, hepatitis C, and human immunodefi-
ciency virus (see Note 1). 
3. The specimens from patients with SLE were de-identified and pre-
existing serum samples that were supplied by W. Clarke; this work 
has been determined to be exempt from IRB review by the Johns 
Hopkins School of Medicine, according to the Code of Federal Reg-
ulations −45 CFR46.101 b. 
2.2 Equipment 
1. A Beckman P/ACE MDQ capillary electrophoresis system was used 
in this study. Other brands or models of CE systems with equiva-
lent performance can also be used. 
2. Spin column desalting column (0.5 mL, 7 kDa cutoff; Thermo Fisher 
Scientific). 
2.3 Buffers and Solutions 
1. 0.5 M Perchloric acid solution, 10 mL: Add 0.429 mL of perchloric 
acid (70%) into a 20 mL glass vial and add 9.571 mL water, giving a 
final perchloric acid concentration of 0.5 M (see Note 2). 
2. 1 M Sodium hydroxide (NaOH) solution, 100 ml: Add 4.0 g of NaOH 
into a 150 mL beaker, add 100 mL of water and dissolve the NaOH 
through stirring or sonication. 
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3. 1 M Hydrochloric acid (HCl) solution, 100 mL: Add 8.333 mL of 37% 
(w/w) HCl into a 100 mL volumetric glassware and add water to 
the mark. 
4. 0.2% (w/v) PEO (viscosity average molecular weight, 8,000,000; 
Sigma-Aldrich) prepared in 0.1 M HCl, 100 mL: Add 0.2 g PEO 
slowly (see Note 3), with stirring, into 100 mL water that is held in 
a container within an 80 °C water bath. Cover the opening of the 
flask with an upside-down 100 mL beaker to avoid water evapora-
tion. Stir the solution for 2 h until all of the PEO has dissolved. Af-
ter this solution has been cooled to room temperature, add 0.833 
mL of 37% of HCl to this solution. 
5. 20 mM Acetate buffer, pH 4.2, containing 0.05% (w/v) PEO and 0.1% 
(w/v) Brij 35, 200 mL: 
Solvent A: 0.05% (w/v) PEO and 0.1% (w/v) Brij 35, 300 mL. Add 0.15 
g PEO slowly, and with stirring, into a container holding 300 mL wa-
ter within an 80 °C water bath. Cover the opening of the flask with an 
upside-down 100 mL beaker to prevent the evaporation of water. Stir 
this solution for an additional 2 h until all of the PEO has dissolved. 
After this solution has been cooled to room temperature, add 0.3 g 
Brij 35 to the solution with stirring. 
Weigh 0.1196 g of sodium acetate trihydrate into a 200 mL beaker. 
Add approximately 180 mL of solvent A into this beaker and stir until 
all the sodium acetate salt has dissolved. Add 178 μL of glacial acetic 
acid to the solution while stirring. Adjust the pH of this solution to 4.2 
by adding small amounts of 1 M NaOH or 1 M HCl and while moni-
toring the pH of solution (see Note 4). Transfer the final solution into 
a 200 mL volumetric glassware and add solvent A to fill this flask to 
the mark (see Note 5). 
2.4 Spin Desalting Column 
Remove the spin column’s bottom closure and loosen the cap with-
out fully removing it. A 2.0 mL microcentrifuge tube can be used as 
a collection tube with its cap removed. Place the column in this col-
lection tube and centrifuge at 6600 rpm (2000 × g) for 1 min to re-
move any storage solution that is present in the device. Place a mark 
on the side of the spin column where the compacted resin is slanted 
upward; this is to make sure the resin is placed the same way after 
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every wash or pre-equilibration step. Place the spin column into a 
minicentrifuge, with the mark facing outward in all subsequent cen-
trifugation steps. Add 300 μL water (i.e., the solution to be used for 
desalting) to the top of the resin bed in the spin column. Centrifuge 
at 6600 rpm for 1 min to remove any water. Repeat the addition of 
water and this centrifugation process two more times, discarding the 
water from the collection tube. 
2.5 Fused Silica Capillary 
A fused silica capillary with a length of 72 cm should be cut from 
capillary tubing with an inner diameter of 50 μm and an outer diam-
eter of 360 μm, as obtained from Polymicro Technologies (Phoenix, 
AZ, USA) (see Note 6). This cut can be achieved by using a cleaving 
stone. Remove the outer polyimide coating from the capillary in the 
desired region of the detection window. This can be done by placing 
the capillary on top of the U-shaped opening of an open-ended = in 
wrench, with this opening being placed at least 11 cm away from the 
near end of the capillary. A lighter can then be used to burn off the 
polyimide coating from the capillary over a length of approximately 5 
mm (see Note 7). This area should then be gently cleaned by using a 
Kimwipe soaked with ethanol. To install the capillary cartridge for the 
P/ACE MDQ CE system, insert the long side of the capillary into the 
outlet side of cartridge. Carefully pull the capillary from the inlet side 
until the detection window appears in the cartridge window. Select 
the required aperture clip (size, 100 × 800 μm) (see Note 8), replace 
from the back of the cartridge, and use an insertion tool to seat the 
O-ring into the front of the aperture (see Note 9). Place seal retainer 
clips on both sides of the capillary and snap these retainer clips into 
position. Place the cartridge face down against the capillary length 
template. Use a cleaving stone to cut and remove the marked portion 
of the capillary. Use the rough side of the cleaving stone to burnish 
the ends of the capillary until these ends are smooth (see Note 10). 
After this step, the final capillary will have an effective length of 50 cm 
and a total length of 60.2 cm. Mount the cartridge with the prepared 
fused silica capillary into the CE system. To clean the capillary and ac-
tivate its interior silanol groups, rinse the capillary with 1 M NaOH for 
30 min at a pressure of 50 psi, and clean the capillary with water for 
10 min at the same pressure [11, 17]. 
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3 Methods 
3.1 Acid Precipitation and Desalting 
1. Acid precipitation: Combine a 65 μL portion of serum and 130 μL of 
0.5 M perchloric acid in a 0.6 mL microcentrifuge tube and vortex 
mix for 20 s. Place the resulting mixture into a minicentrifuge and 
allow it to spin at 6600 rpm for 10 min at room temperature. This 
step precipitates major proteins from serum while allowing AGP to 
be recovered in the supernatant [21]. 
2. Sample desalting: Place a 130 μL portion of the supernatant from 
the acid precipitation step into a spin desalting column. Place the 
spin desalting column into a 2.0 mL microcentrifuge tube with the 
cap removed as a collection tube and spin the column for 2 min 
at 6600 rpm. 
This desalting step helps to improve both the loading capac-
ity and extent of zone broadening in the final CE method through 
its effect on the relative resistivity (or conductivity) for the sam-
ple solution versus the running buffer, as is illustrated in Fig. 3 
[17]. The use of both acid precipitation and desalting for sample 
Fig. 3 Electropherograms obtained for AGP glycoforms when using human serum 
that has been processed by desalting or that was used with no sample pretreat-
ment. This figure is modified with permission from Ref. [17].  
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preparation has also been found to result in good recoveries for 
AGP glycoforms from serum. For instance, recoveries between 
72.3 and 80.9% have been measured when using this pretreat-
ment method to look at AGP glycoform bands from human se-
rum by CE (see Table 1) [17]. 
3. Sample dilution: Add the filtrate from the previous step to a 20 ml 
glass vial that also contains 5 mL of water (see Note 11). This step 
is used to reduce the concentration of AGP down to around 1 μg/
mL and generates a relatively large volume of a working sample 
solution that can be employed for multiple injections, or reanaly-
sis as needed. 
3.2 Capillary Electrophoresis and Electrophoretic Injection 
1. CE operating conditions: The following conditions are used for the 
final method that is described in this report. The capillary temper-
ature should be maintained at 25 °C during the separation, and 
the applied voltage for the separation should be set at −30 kV (see 
Note 12). AGP glycoforms can be detected by using their absor-
bance at 200 nm [11, 17]. 
Table 1 Characteristics of an electrophoretic injection CE method for AGP glycoform analy-
sis in serum using acid precipitation and desalting for sample pretreatment 
Glycoform Limit of  Precision of Precision of  
band detection (nM)a migration timeb peak areab  Recoveryc  
3  2.5  ±0.08%  ±0.86%  72.3% 
4  8.2  ±0.11%  ±0.94%  80.9% 
5  11.4  ±0.12%  ±0.71%  80.4% 
6  8.5  ±0.12%  ±0.52%  80.5% 
7  4.8  ±0.12%  ±0.34%  80.3% 
8  2.4  ±0.13%  ±0.86%  78.2% 
9  2.1  ±0.12%  ±1.18%  73.6% 
Adapted with permission from Ref. [17]
a. The detection limit was calculated by using a signal-to-noise ratio of three, as based on the 
standard deviation of the intercept and the slope from a calibration curve for this assay
b. The relative standard deviations listed in these columns are based on measurements made 
in triplicate (n = 3) for normal serum that was spiked with 2.5 g/L AGP. The ranges shown 
represent ±1 relative standard deviation
c. The recovery was calculated by dividing the slopes of the corresponding calibration curves 
that were obtained before and after sample pretreatment with normal serum that had 
been spiked with a known amount of AGP  
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2. Preparation of static and dynamic coatings of PEO: The capillary is 
first cleaned by using a 5 min rinse with 1 M NaOH, followed by a 3 
min rinse with water. The coating is applied by rinsing the capillary 
for 5 min with 1 M HCl and then rinsing for 5 min with a 0.2% (w/v) 
PEO solution that contains 0.1M HCl. The capillary is then rinsed 
for 5 min with a running buffer that consists of pH 4.2, 20 mM ac-
etate buffer containing 0.05% (w/v) PEO and 0.1% (w/v) Brij 35. All 
of these rinse steps should be performed at an applied pressure of 
50 psi, and this rinsing procedure should be repeated before each 
CE separation. The effects of changing the buffer pH, capillary coat-
ing material or concentration of Brij 35 on the separation of AGP 
glycoforms are discussed under Note 13. 
3. Electrophoretic injection: Add 1.2 mL of the sample to a buffer vial. 
Carry out electrophoretic injection by using a voltage of −5 kV that 
is applied for 5 min (see Note 14). 
This electrophoretic injection step enables selective injection of 
AGP from a sample that has undergone the pretreatment steps de-
scribed under Subheading 3.1. The selectivity of this approach is 
aided by the fact that AGP is one of few proteins that can have a 
negative charge at an acidic pH around 4 [22]. The use of an injec-
tion time longer than 5 min can result in a higher loading capac-
ity and signal intensity for AGP, as illustrated in Fig. 4a; however, a 
lower resolution will also be observed under these conditions due 
Fig. 4 Relationship between (a) the total peak area for AGP glycoform bands and 
the time used for electrophoretic injection, and (b) the width for the ninth glyco-
form band for AGP versus the time used for electrophoretic injection. The error bars 
represent a range of ±1 S.D. (n = 3) in (a) and a range of ±1 S.D. of the mean (n = 
3) in (b). The plots used in this figure were adapted with permission from Ref. [17]. 
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to the zone broadening that occurs during injection, as shown in 
Fig. 4b. In contrast, the use of an injection time that is shorter than 
5 min will result in smaller signal intensity with similar broadening 
to what is seen at an injection time of 5 min. Based on these trends, 
an injection time of 5 min has been determined to provide a good 
compromise between detection limits, overall analysis times, and 
peak resolution [17]. 
4. Capillary cleaning and storage: After a single separation or multiple 
separations that are carried out as a sequence, the capillary should 
be rinsed with 1 M NaOH at 50 psi for 15 min and then rinsed with 
water at 50 psi for 10 min. The capillary should be stored in water 
when it is not in use (see Note 15). 
3.3 Data Analysis 
Most of the following procedures for data analysis are specific for 
the type of CE system and analysis software that were used in this 
study. Equivalent procedures can be employed with alternative CE 
systems or software. 
1. An electropherogram that has been obtained by the CE system can 
be exported as a .cdf file for analysis of its peaks by a program such 
as Peakfit version 4.12. 
2. Use the “section” option to select a specific region of the electro-
pherogram for closer analysis (i.e., a suggested range of 10–25 min 
for most applications of this CE method). 
3. To carry out a baseline correction using Peakfit, select the “progres-
sive line” option. This option can be used to correct for artifacts 
such as baseline drifting. 
4. When using Peakfit for data analysis, select the options “Chroma-
tography” and “Exponentially modified Gaussian or EMG” for peak 
type. Select the options “Vary widths,” “Vary shape,” and “Allow neg-
ative” for auto scan. Click on the electropherogram to add multiple 
simulated peaks and adjust their shape to give an approximate fit 
to the electropherogram. 
5. When using Peakfit, select and click the button that says “Fast peak 
fit with numerical update” until the best fit is obtained. Next, select 
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and click the options “Review fit” and “Numeric” to acquire the 
measured parameters for each individual peak or band. To obtain 
more parameters for the simulated peaks, select “Options” to add 
in additional factors such as “Chromatography analysis.” 
3.4 Analysis of AGP Glycoform Bands in Serum Samples 
1. The electropherograms in Fig. 5a show some typical results that 
were obtained by the overall sample pretreatment and CE method 
for normal and SLE serum samples. The migration times and peak 
areas of the individual glycoform bands in these electropherograms 
were obtained by following the data analysis procedures that were 
described under Subheading 3.3. 
2. The total peak area for AGP in the electropherogram can be ob-
tained in this particular method by using a summation of the peak 
areas for the individual glycoform bands (see Note 16). A correction 
of the peak areas based on their apparent mobilities, as is common 
in other CE methods, is not needed in this approach with negligible 
electroosmosis because the bias of peak area in detection due to 
differential mobility has already been corrected during the electro-
phoretic injection process [17]. The relative peak area due to each 
Fig. 5 (a) Electropherograms obtained for AGP from SLE serum or pooled normal 
serum, in which the mobility marker (Lucifer yellow CH, LyCH) was introduced by 
hydrodynamic injection after sample injection. (b) Glycoform patterns obtained for 
AGP from SLE serum or pooled normal serum by this CE method; the error bars 
shown for the migration times and % peak areas represent ±1 S.D. of the mean (n 
= 3). These plots are reproduced with permission from Ref. [17].  
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individual band can be found by dividing the separate band/peak 
areas by the total peak band/peak for AGP. 
3. The glycoform band distribution pattern for AGP can be visualized 
by making a plot of the percentage peak area for each glycoform 
band (placed on the y-axis) versus the migration time of each indi-
vidual band (on the x-axis) [17]. Examples of such plots are shown 
in Fig. 5b. 
4. This sample preparation and CE method has been found to have a 
limit of detection ranging from 2.1 to 11.3 nM for the major glyco-
form bands of AGP in human serum [17]. These limits of detection 
are approximately 3000-fold lower than the concentration of AGP 
that is normally observed in human serum and allow this method 
to be used with only 65 μl of serum without the need for any sam-
ple labeling [17]. 
5. The precision of the migration times for the AGP glycoform bands 
is between ±0.08 and 0.13%; the precisions for the peak areas are 
between ±0.34 and 1.18% when using an internal standard to cor-
rect the peak areas for their variations in loading capacity during 
the injection process (see Table 1). This reproducible separation al-
lows the direct use of migration times to identify and distinguish 
between AGP glycoform bands in this method [17]. 
4 Notes 
1. Any work with human samples such as serum that may contain blood-
borne pathogens should be handled according to appropriate biosafety 
protocols and in BSL-2 facilities. 
2. Use appropriate chemical hazard precautions and facilities when handling 
perchloric acid [23]. 
3. This step is to avoid the formation of aggregates of PEO, which will be 
difficult to dissolve. 
4. Be sure to calibrate the pH meter before use, as the separation of AGP 
glycoforms by CE can be sensitive to a small change in the pH of the run-
ning buffer [11]. 
5. Do not filter this buffer solution because the PEO may not be able to pass 
through the filter (e.g., one using a 0.2 μm pore size membrane). 
6. The protocol described in this report has been developed for these par-
ticular capillary dimensions. The use of other capillary dimensions will 
Zhang ,  Clarke  &  Hage  in  Ph i l l i p s ,  ed . ,  Cl in ical  Appl icat ions   ( 2019 )       14
affect the resolution, overall analysis time, and peak broadening that are 
obtained in the final method, and will require further optimization of pa-
rameters such as the applied voltage and capillary pretreatment/rinsing 
protocol, among other factors. 
7. Extra care needs to be taken when handling a capillary that contains a 
region without a polyimide coating because the exposed region of this 
capillary can be quite brittle. 
8. Make sure the O-ring has been removed from the aperture clip before 
installing the aperture clip. A preinstalled O-ring inside the aperture clip 
can crack the capillary when you are installing the aperture clip. 
9. Make sure the O-ring lays flat after its installation. An improper orienta-
tion of the O-ring will block the light path and create resistance when 
connecting the optical fiber with the aperture clip. 
10. A magnifying lens can be used to inspect the end of capillary. A rough 
end on the capillary will result in a tailing effect for all the AGP glycoform 
bands in the final method and should be avoided. 
11. The remaining contents of the serum sample are diluted by 115.4-fold 
as a result of the overall pretreatment procedure. 
12. An applied voltage of −30 kV is the highest setting that is available in 
the CE system that was used in this work. A lower applied voltage can be 
used but will generate a smaller electric field, leading to reduced migra-
tion speeds and longer analysis times. The peaks or bands will also ap-
pear broader in the time domain under lower voltage conditions. 
13. Several other pH conditions have been evaluated for use with this 
method. When using a pH range of 3.8 to 5.0 for the running buffer, it 
was found that the best compromise between resolution and peak broad-
ening was obtained at pH 4.2 [11]. As is shown in Fig. 6, an increase in 
resolution was observed for AGP glycoform bands in going from pH 5.0 
to 4.2; however, the zone broadening increased and led to a reduction in 
resolution when going from pH 4.2 to 3.8. 
The effect of changing the concentration of Brij 35 as a buffer additive 
has been evaluated over the range of 0 to 0.5% (w/v). It was found that 
the use of 0.1% Brij 35 gave the best resolution for the glycoform bands, 
as is illustrated in Fig. 7 [11]. 
Table 2 compares the results that were obtained when using various 
types of coatings for the CE capillary. It was found that the use of PEO as 
both a static and dynamic coating reagent resulted in the greatest reduc-
tion of electroosmotic flow and the shortest overall analysis time when 
compared to capillary coatings based on poly(vinyl alcohol) (or PVA) or 
dextran for the separation of AGP glycoforms [11]. 
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Fig. 7 Average resolution obtained for AGP glycoform bands by CE as a function 
of the concentration of Brij 35 that was placed into the running buffer. This figure 
was reproduced with permission from Ref. [11]. The error bars represent a range of 
±1 S.D. (n = 3).  
Fig. 6 Electropherograms showing the effect of pH on the separation and resolu-
tion of AGP glycoform bands by CE. This figure is reproduced with permission from 
Ref. [11].  
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14. The “inject” event during the method program has a time limit of up to 
99 s. For the particular CE system that was employed in this study, a “sep-
arate” event can be used instead for sample injection during the method 
program for applying a voltage for 5 min. The sample can be added to a 
2.0 mL vial and placed into the buffer tray to use this event. 
Every sample vial is only used for injection once in this approach be-
cause electrophoretic injection will deplete AGP from the sample vial 
without depleting the buffer or solvent. This means the concentration 
of AGP in the original sample vial will be reduced after even a single in-
jection step. 
15. This procedure should be performed right away after a separation se-
quence or multiple separations to avoid the permanent adsorption of 
serum proteins to the inner surface of the capillary, as may occur if this 
capillary has been left unrinsed for a long time. 
16. The peak area obtained by this method represents the true value with-
out bias due to differences in the mobilities of the separate AGP glyco-
form bands [17]. When two analytes with the same quantity are injected 
by this approach, the analyte peak that has the longer migration time will 
have a larger area than the peak for the second analyte with the shorter 
migration time. This bias effect is automatically corrected during elec-
trophoretic injection because a smaller amount is injected for an analyte 
with a smaller apparent mobility. More details on the theory of this ap-
proach can be found in Ref. [17]. 
  
Table 2 Effect on electroosmotic flow when using various modification agents and methods 
to treat fused silica capillariesa 
 Mobility due to  Reduction in 
 electroosmotic flow,  electroosmotic flow 
Modification agent and method   μosm (× 10−3cm2min−1V−1)  (%) 
Poly(vinyl alcohol) (or PVA) – Permanent coating  7.05 (±0.02)  65.8 (±1.4)
PVA – Permanent plus dynamic coating  7.09 (±0.23)  66.8 (±1.8)
PVA – Static coating  11.04 (±0.27)  48.0 (±2.6)
PVA – Static plus dynamic coating  9.85 (±0.06)  52.3 (±2.0)
Poly (ethylene oxide) (or PEO) – Static coating  1.83 (±0.01)  91.1 (±0.4)
PEO – Static plus dynamic coating  0.222 (±0.002)  98.9 (±0.1)
Dextran – Static coating  9.76 (±0.01)  52.8 (±2.0)
Dextran – Static plus dynamic coating  9.89 (±0.10)  51.7 (±2.1)
Reproduced with permission from Ref. [11]
a. The mobility due to electroosmotic flow for a fused silica capillary was 20.66 (±0.87) × 
10−3 cm2 min−1 V−1. The electroosmotic flow was measured in pH 4.2, 20 mM acetate buf-
fer with a sample containing 1.0 g/L thiourea in water. All of the results represent the av-
erage of three trials, where the number in parentheses corresponds to a range of ±1 S.D 
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